tirzepatide and glaucoma Use of the dual GIP/GLP-1 drug (Mounjaro, Zepbound) was associated with a significantly reduced risk of compared with GLP-1 drugs among patients with type 2 diabetes, a large retrospective cohort Is Tirzepatide Easier on the
Description
Thirdly Use within 56 days after first use
Dose changes should be based on the treatment plan, glucose readings, tolerability, and clinical judgment rather than pen stretching, price concerns, or convenience
Using genetic predisposition data alongside clinical biomarkersferritin, vitamin D, thyroid function, albuminenables a comprehensive risk profile
Contributor Information Dariush Mozaffarian, Email: [email protected]
Enhanced lipolysis in the adipose tissues of insulin resistant patients enhances the influx of FFAs to the liver which in turn worsens hepatic steatosis and insulin resistance
